WO2003104146A1 - Method of obtaining a buffered hypertonic solution and solution thus obtained - Google Patents
Method of obtaining a buffered hypertonic solution and solution thus obtained Download PDFInfo
- Publication number
- WO2003104146A1 WO2003104146A1 PCT/ES2003/000280 ES0300280W WO03104146A1 WO 2003104146 A1 WO2003104146 A1 WO 2003104146A1 ES 0300280 W ES0300280 W ES 0300280W WO 03104146 A1 WO03104146 A1 WO 03104146A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- obtaining
- hypertonic
- phosphate
- buffered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/30—Alkali metal phosphates
- C01B25/301—Preparation from liquid orthophosphoric acid or from an acid solution or suspension of orthophosphates
Definitions
- the following invention refers to a procedure for obtaining a buffered hypertonic solution, being applied in therapeutics as an intestinal evacuant, so that the present procedure is aimed at obtaining a hypertonic saline solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2.
- the hypertonic saline solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2 is obtained from a reaction of phosphoric acid and sodium hydroxide to be poured, simultaneously and at different rates, into a reactor containing deionized water, Maintaining continuous agitation.
- the process comprises the simultaneous addition, preferably, of 75% phosphoric acid and 50% sodium hydroxide.
- the aqueous solution may contain between 6% and 26% of dodecahydrate bisodic phosphate and between 12% and 52% of monohydrate monosodium phosphate, according to the weight / volume percentage, maintaining the ratio of 1: 2 in said solution. .
- SCOPE saline solution of bisodic phosphate and monosodium phosphate that is presented, is of therapeutic application as an intestinal evacuant.
- saline solutions must have a hypertonic character, due to which, when acting on the intestinal walls, there will be, by osmotic action, a water supply from inside the cells and intercellular spaces to the intestinal lumen that contains the hypersonic saline solution, to balance the concentration and approach an isotonic solution, with which a physiological and effective intestinal cleansing would be achieved.
- hypertonic physiological saline solutions that have been obtained from salts of different basicity have been known for some time, but these solutions have the disadvantage of destroying or at least altering the intestinal flora, therefore, it was a task of the technique to find a procedure for obtaining hypertonic saline solutions that do not pathologically alter the intestinal flora while achieving a physiological cleansing of the intestine as complete as possible.
- the process of the invention also presented the advantage that the solutions obtained are perfectly reproducible and rigorously standardizable, whatever the initial richness of the products used or their content in water of crystallization.
- the process of the invention was characterized in that it consisted of forming an aqueous solution of bisodic phosphate and which was reacted with phosphoric acid until the new solution formed had a certain pH, and it was also possible to start from a solution of monosodium phosphate and neutralize with soda until reaching the predetermined pH.
- aqueous solutions obtained by the process of the invention have an extraordinary stability over time, which also makes them suitable for use as physiological solutions.
- a process for obtaining a buffered hypertonic solution is described herein, being of the type of saline solutions that have a constant pH and are minutes for therapeutic application, so that the procedure comprises the simultaneous addition, at different rates, of phosphoric acid and sodium hydroxide, on deionized water, obtaining an aqueous solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2 in said solution.
- the aqueous solution may contain between 6% and 26% of dodecahydrate bisodic phosphate and between 12% and 52% of monohydrate monosodium phosphate, maintaining the ratio of 1: 2 in said solution.
- the process comprises the simultaneous addition of 75% phosphoric acid and 50% sodium hydroxide, while continuing to stir the mixture.
- the aqueous solution contains 8% dodecahydrate bisodium phosphate and 16% monohydrate monosodium phosphate, according to the weight / volume percentage.
- the aqueous solution contains 24% dodecahydrate bisodium phosphate and 48% monohydrate monosodium phosphate, according to the weight / volume percentage.
- Figure 1 It shows a view in which, schematically, it is observed how a phosphoric acid and sodium hydroxide are poured onto a deionized water container reactor, maintaining a continuous stirring of the mixture. MODE OF CARRYING OUT THE INVENTION.
- the present invention is further illustrated by the following example in an illustrative manner and in no way limiting. EXAMPLE.
- the saline solution obtained is of therapeutic application as a bowel movement.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method of obtaining a buffered hypertonic solution
and the solution thus obtained, said solution being of the type of saline solutions
with a constant pH which can be used in therapeutics. The inventive method consists
in adding phosphoric acid (3) and sodium hydroxide (4) to deionised water (2)
in a reactor (1), simultaneously but at different speeds, thereby producing
an aqueous solution of disodium phosphate and monosodium phosphate in a proportion
of 1:2 in said solution.
Description
PROCEDIMIENTO PARA LA OBTENCIÓN DE UNA SOLUCIÓN PROCEDURE FOR OBTAINING A SOLUTION
HIPERTÓNICA TAMPONADA Y SOLUCIÓN OBTENIDASTAMPED HYPERTONICS AND SOLUTION OBTAINED
OBJETO DE LA INVENCIÓN.OBJECT OF THE INVENTION
La siguiente invención, según se expresa en el enunciado de la presente memoria descriptiva, se refiere un procedimiento para la obtención de una solución hipertónica tamponada, siendo de aplicación en terapéutica como evacuante intestinal, de forma que el presente procedimiento tiene por objeto la obtención de una solución salina hipertónica de fosfato bisódico y fosfato monosódico en una proporción de 1 :2.The following invention, as expressed in the statement of the present specification, refers to a procedure for obtaining a buffered hypertonic solution, being applied in therapeutics as an intestinal evacuant, so that the present procedure is aimed at obtaining a hypertonic saline solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2.
Así, la solución salina hipertónica de fosfato bisódico y fosfato monosódico en una proporción de 1:2, es obtenida a partir de una reacción de ácido fosfórico e hidróxido sódico ai ser vertidos, simultáneamente y a distinta velocidad, en un reactor que contiene agua desionizada, manteniendo una continua agitación.Thus, the hypertonic saline solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2, is obtained from a reaction of phosphoric acid and sodium hydroxide to be poured, simultaneously and at different rates, into a reactor containing deionized water, Maintaining continuous agitation.
De esta forma, el procedimiento comprende la adición simultánea, preferentemnete, de ácido fosfórico al 75% y de hidróxido sódico al 50%.In this way, the process comprises the simultaneous addition, preferably, of 75% phosphoric acid and 50% sodium hydroxide.
Asimismo, la solución acuosa puede contener entre un 6% y un 26% de fosfato bisódico dodecahidratado y entre un 12% a un 52% de fosfato monosódico monohidratado, según el porcentaje peso/volumen, manteniendo la proporción de 1 :2 en dicha solución.Also, the aqueous solution may contain between 6% and 26% of dodecahydrate bisodic phosphate and between 12% and 52% of monohydrate monosodium phosphate, according to the weight / volume percentage, maintaining the ratio of 1: 2 in said solution. .
CAMPO DE APLICACIÓN. La solución salina de fosfato bisódico y fosfato monosódico que se presenta, es de aplicación terapéutica como evacuante intestinal.SCOPE. The saline solution of bisodic phosphate and monosodium phosphate that is presented, is of therapeutic application as an intestinal evacuant.
ANTECEDENTES DE LA INVENCIÓN. Como es conocido, en proctología es necesario disponer de un abundante volumen de soluciones salinas, para su uso como evacuantes intestinales, que presenten un pH constante y que sean aptas para su aplicación en terapéutica.BACKGROUND OF THE INVENTION As is known, in proctology it is necessary to have an abundant volume of saline solutions, for use as intestinal evacuators, which have a constant pH and that are suitable for therapeutic application.
Estas soluciones salinas deben presentar un carácter hipertónico, debido al cual, al actuar sobre las paredes intestinales se producirá, por acción osmótica, un aporte hídrico desde el interior de las células y los espacios intercelulares hacia la luz intestinal que contiene la solución salina hipersónica, para equilibrar la
concentración y aproximarse a una solución isotónica, con la que se lograría una limpieza intestinal fisiológica y eficaz.These saline solutions must have a hypertonic character, due to which, when acting on the intestinal walls, there will be, by osmotic action, a water supply from inside the cells and intercellular spaces to the intestinal lumen that contains the hypersonic saline solution, to balance the concentration and approach an isotonic solution, with which a physiological and effective intestinal cleansing would be achieved.
Así, hace tiempo que se conocen soluciones salinas fisiológicas hipertónicas que se obtienen a partir de sales de distinta basicidad, pero estas soluciones presentan el inconveniente de destruir o al menos alterar la flora intestinal por lo cual, era un cometido de la técnica el encontrar un procedimiento para la obtención de soluciones salinas hipertónicas que no alterasen patológicamente la flora intestinal a la vez que consiguiesen una limpieza fisiológica del intestino tan completa como fuese posible.Thus, hypertonic physiological saline solutions that have been obtained from salts of different basicity have been known for some time, but these solutions have the disadvantage of destroying or at least altering the intestinal flora, therefore, it was a task of the technique to find a procedure for obtaining hypertonic saline solutions that do not pathologically alter the intestinal flora while achieving a physiological cleansing of the intestine as complete as possible.
Con objeto de solventar dicho inconveniente, en la patente n°. 404.975 se reivindicó un "procedimiento para la obtención de una solución hipertónica tamponada", la cual presentaba un pH constante y no irritante, que venia a remediar ios inconvenientes de las soluciones salinas hipertónicas ya conocidas.In order to solve said inconvenience, in patent no. 404,975 claimed a "procedure for obtaining a buffered hypertonic solution", which had a constant and non-irritating pH, which came to remedy the disadvantages of hypertonic saline solutions already known.
El procedimiento que constituyó el objeto de la citada patente n°. 404.975, se basó en el hecho de que las soluciones tampón de las sales monosódicas y bisódicas del ácido fosfórico, presentan interesantes propiedades hipertónicas a la vez que su pH es perfectamente tolerado por el organismo.The procedure that constituted the object of said patent n °. 404.975, was based on the fact that the buffer solutions of the monosodium and bisodic salts of phosphoric acid have interesting hypertonic properties while their pH is perfectly tolerated by the body.
El procedimiento de la invención presentó, además, la ventaja de que las soluciones obtenidas son perfectamente reproducibles y rigurosamente estandarizables, sea la que fuera la riqueza inicial de los productos utilizados o de su contenido en agua de cristalización. Así, el procedimiento de la invención se caracterizó porque consistía en formar una solución, acuosa, de fosfato bisódico y a la cual se hacia reaccionar con ácido fosfórico hasta que la nueva solución formada presentase un pH determinado, y asimismo era posible partir de una solución de fosfato monosódico y neutralizar con sosa hasta alcanzar el pH predeterminado.The process of the invention also presented the advantage that the solutions obtained are perfectly reproducible and rigorously standardizable, whatever the initial richness of the products used or their content in water of crystallization. Thus, the process of the invention was characterized in that it consisted of forming an aqueous solution of bisodic phosphate and which was reacted with phosphoric acid until the new solution formed had a certain pH, and it was also possible to start from a solution of monosodium phosphate and neutralize with soda until reaching the predetermined pH.
Cuando la solución formada presenta un pH cercano al 6, sus propiedades hipertónicas son excelentes, a la vez que dicho pH es perfectamente tolerable por el organismo sin producir destrucción de la flora ni irritación intestinal. Se observó igualmente, y esto constituyó otra característica del
procedimiento, que cuando se alcanzaba el pH predeterminado en la solución, la proporción entre sal bisódica del ácido fosfórico y sal monosódica de dicho ácido es de 1 a 2, pudiéndose demostrar la existencia de estas dos sales, y su proporción en la solución, por cualquier medio de análisis clásico de las sales del ácido fosfórico.When the solution formed has a pH close to 6, its hypertonic properties are excellent, while said pH is perfectly tolerable by the body without causing destruction of the flora or intestinal irritation. It was also observed, and this constituted another characteristic of procedure, that when the predetermined pH in the solution was reached, the proportion between phosphoric acid bisodic salt and monosodium salt of said acid is from 1 to 2, being able to demonstrate the existence of these two salts, and their proportion in the solution, by any means of classical analysis of phosphoric acid salts.
Por otra parte, podemos citar, igualmente, el Certificado de Adición n°. 532.000 a la Patente n°. 404.975 antes reseñada, el cual se basa en que la solución salina estable obtenida y reivindicada en la Patente principal, con pH próximo a 6, y en las proporciones de sales correspondientes, puede también obtenerse a partir de la reacción de ácido fosfórico e hidróxido sódico, de forma que al ácido fosfórico del 75 % se añade agua y una solución de hidróxído sódico al 50%. Esta incorporación debe realizarse a una velocidad inferior a 0,67 I/minuto dado lo altamente exotérmica que es la reacción, así como con agitación constante.On the other hand, we can also cite the Certificate of Addition no. 532,000 to Patent No. 404.975 described above, which is based on the fact that the stable saline solution obtained and claimed in the main patent, with a pH close to 6, and in the proportions of corresponding salts, can also be obtained from the phosphoric acid and sodium hydroxide reaction , so that to the 75% phosphoric acid water and a 50% sodium hydroxide solution are added. This incorporation must be carried out at a rate of less than 0.67 I / minute given the highly exothermic reaction, as well as with constant agitation.
Asimismo, es posible preparar soluciones concentradas que posteriormente, por dilución, pueden dar la solución idónea para el uso de evacuante intestinal.Likewise, it is possible to prepare concentrated solutions that subsequently, by dilution, can give the ideal solution for the use of intestinal evacuant.
Las soluciones acuosas obtenidas por el procedimiento de la invención, presentan una extraordinaria estabilidad en el tiempo, lo cual las hace asimismo aptas para su uso como soluciones fisiológicas.The aqueous solutions obtained by the process of the invention have an extraordinary stability over time, which also makes them suitable for use as physiological solutions.
DESCRIPCIÓN DE LA INVENCIÓN. En la presente memoria se describe un procedimiento para la obtención de una solución hipertónica tamponada, siendo del tipo de soluciones salinas que presentan un pH constante y son actas para su aplicación terapéutica, de forma que el procedimiento comprende la adición simultánea, a distinta velocidad, de ácido fosfórico e hidróxido sódico, sobre agua desionizada, obteniendo una solución acuosa de fosfato bísódico y fosfato monosódico en una proporción de 1:2 en dicha solución.DESCRIPTION OF THE INVENTION A process for obtaining a buffered hypertonic solution is described herein, being of the type of saline solutions that have a constant pH and are minutes for therapeutic application, so that the procedure comprises the simultaneous addition, at different rates, of phosphoric acid and sodium hydroxide, on deionized water, obtaining an aqueous solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2 in said solution.
La solución acuosa puede contener entre un 6% y un 26% de fosfato bisódico dodecahidratado y entre un 12% a un 52% de fosfato monosódico monohidratado, manteniendo la proporción de 1:2 en dicha solución.
Preferentemente, el procedimiento comprende la adición simultánea de ácido fosfórico al 75% y de hidróxido sódico al 50%, manteniendo una continua agitación de la mezcla.The aqueous solution may contain between 6% and 26% of dodecahydrate bisodic phosphate and between 12% and 52% of monohydrate monosodium phosphate, maintaining the ratio of 1: 2 in said solution. Preferably, the process comprises the simultaneous addition of 75% phosphoric acid and 50% sodium hydroxide, while continuing to stir the mixture.
De esta forma, al añadir simultáneamente el ácido fosfórico y el hidróxido sódico sobre el agua desionizada contenida en el correspondiente reactor, se produce una reacción considerablemente menos exotérmica que la reacción producida por los medios convencionales, citados en el apartado "antecedentes de la invención", con la gran ventaja que ello representa. En una primera ejecución preferente de la invención, la solución acuosa contiene un 8% de fosfato bisódico dodecahidratado y un 16% de fosfato monosódico monohidratado, según el porcentaje peso/volumen.In this way, by adding phosphoric acid and sodium hydroxide simultaneously to the deionized water contained in the corresponding reactor, a considerably less exothermic reaction occurs than the reaction produced by conventional means, cited in the "background of the invention" section. , with the great advantage that this represents. In a first preferred embodiment of the invention, the aqueous solution contains 8% dodecahydrate bisodium phosphate and 16% monohydrate monosodium phosphate, according to the weight / volume percentage.
Por otra parte, en una segunda ejecución preferente de la invención, la solución acuosa contiene un 24% de fosfato bisódico dodecahidratado y un 48% de fosfato monosódico monohidratado, según el porcentaje peso/volumen.On the other hand, in a second preferred embodiment of the invention, the aqueous solution contains 24% dodecahydrate bisodium phosphate and 48% monohydrate monosodium phosphate, according to the weight / volume percentage.
Para complementar la descripción que seguidamente se va a realizar, y con objeto de ayudar a una mejor comprensión de las características de la invención, se acompaña a la presente memoria descriptiva, de un juego de planos, en cuyas figuras de forma ilustrativa y no limitativa, se representan los detalles más característicos de la invención.To complement the description that is going to be carried out below, and in order to help a better understanding of the characteristics of the invention, this descriptive report is accompanied by a set of drawings, whose figures are illustrative and not limiting , the most characteristic details of the invention are represented.
BREVE DESCRIPCIÓN DE LOS DISEÑOS. Figura 1. Muestra una vista en la que, de forma esquemática, se observa como sobre un reactor contenedor de agua desionizada se vierte, simultáneamente y a distinta velocidad, ácido fosfórico e hidróxido sódico, manteniendo una continua agitación de la mezcla. MODO DE REALIZACIÓN DE LA INVENCIÓN. La presente invención se ilustra adicionalmente mediante el siguiente ejemplo de forma ilustrativa y en modo alguno limitativo. EJEMPLO.BRIEF DESCRIPTION OF THE DESIGNS. Figure 1. It shows a view in which, schematically, it is observed how a phosphoric acid and sodium hydroxide are poured onto a deionized water container reactor, maintaining a continuous stirring of the mixture. MODE OF CARRYING OUT THE INVENTION. The present invention is further illustrated by the following example in an illustrative manner and in no way limiting. EXAMPLE.
En un reactor 1 se incorporaron 1500 litros de agua desionizada 2, procediéndose a su agitación, y a la incorporación de 2Kg. de Nipagín Sódico, continuando su agitación.
A continuación se procedió a la automática, y simultánea, adición de 463 litros de ácido fosfórico al 75% a una velocidad de 1680 l/h. y 337 litros de hidróxido sódico al 50% a una velocidad de 1220 l/h., manteniendo su agitación. En el sencillo diseño adjunto vemos como en el reactor 1, dotado del correspondiente agitador, se han incorporado 1500 litros de agua desionizada 2, procediéndose a la posterior adición, de forma simultánea y a distinta velocidad, de ácido fosfórico 3 al 75% e hidróxido sódico 4 al 50%. De esta forma, se obtuvo una solución salina fisiológica hipertónica de fosfato bisódico dodecahidratado y fosfato monosódico monohidratado con un porcentaje del 12% y 24%, es decir, según una relación de 1:2, comprendiéndose su pH entre un 5,3 a un 5,6 a 25° C.In a reactor 1 1500 liters of deionized water 2 were incorporated, stirring, and the incorporation of 2Kg. of Nipagín Sodico, continuing its agitation. Subsequently, the automatic and simultaneous addition of 463 liters of 75% phosphoric acid was carried out at a speed of 1680 l / h. and 337 liters of 50% sodium hydroxide at a speed of 1220 l / h., maintaining its stirring. In the simple design attached we see how in reactor 1, equipped with the corresponding stirrer, 1500 liters of deionized water 2 have been incorporated, proceeding to the subsequent addition, simultaneously and at different rates, of phosphoric acid 3 to 75% and sodium hydroxide 4 to 50%. In this way, a hypertonic physiological saline solution of bisodic phosphate dodecahydrate and monosodium phosphate monohydrate with a percentage of 12% and 24% was obtained, that is, according to a ratio of 1: 2, its pH being comprised between 5.3 to a 5.6 at 25 ° C.
La solución salina obtenida es de aplicación terapéutica como evacuante intestinal.
The saline solution obtained is of therapeutic application as a bowel movement.
Claims
R E I V I N D I C A C I O N E S. 1a.- PROCEDIMIENTO PARA LA OBTENCIÓN DE UNA SOLUCIÓN HIPERTÓNICA TAMPONADA, siendo del tipo de soluciones salinas que presentan un pH constante y son aptas para su aplicación terapéutica, caracterizado porque el procedimiento comprende la adición simultánea, a distinta velocidad, de ácido fosfórico (3) e hidróxido sódico (4), sobre agua desionizada (2) contenida en un reactor (1), obteniendo una solución acuosa de fosfato bisódico y fosfato monosódico en una proporción de 1:2 en dicha solución. 2a.- PROCEDIMIENTO PARA LA OBTENCIÓN DE UNA SOLUCIÓNREIVINDICACIONE S. 1 a .- PROCEDURE FOR OBTAINING A STAMPED HYPERTONIC SOLUTION, being of the type of saline solutions that have a constant pH and are suitable for therapeutic application, characterized in that the procedure comprises the simultaneous addition, at different speeds, of phosphoric acid (3) and sodium hydroxide (4), on deionized water (2) contained in a reactor (1), obtaining an aqueous solution of bisodic phosphate and monosodium phosphate in a ratio of 1: 2 in said solution. 2 a .- PROCEDURE FOR OBTAINING A SOLUTION
HIPERTÓNICA TAMPONADA, según reivindicación 1a, caracterizado porque el procedimiento comprende la adición simultánea de ácido fosfórico al 75% y de hidróxido sódico al 50%.HYPERTONIC buffered, according to claim 1, wherein the process comprises simultaneous addition of phosphoric acid at 75% and sodium hydroxide at 50%.
3a.- SOLUCIÓN OBTENIDA POR EL PROCEDIMIENTO PARA LA OBTENCIÓN DE UNA SOLUCIÓN HIPERTÓNICA TAMPONADA, según reivindicación 1a, caracterizada porque la solución acuosa puede contener entre un 6% y un 26% de fosfato bisódico dodecahidratado y entre un 12% a un 52% de fosfato monosódico monohidratado, según el porcentaje peso/volumen, manteniendo la proporción de 1:2 en dicha solución.3 .- SOLUTION OBTAINED BY THE PROCESS FOR OBTAINING A HYPERTONIC SOLUTION buffered, according to claim 1, wherein the aqueous solution can contain between 6% and 26% of disodium phosphate dodecahydrate and between 12% to 52 % monosodium phosphate monohydrate, according to the percentage weight / volume, maintaining the ratio of 1: 2 in said solution.
4a.- SOLUCIÓN OBTENIDA POR EL PROCEDIMIENTO PARA LA OBTENCIÓN DE UNA SOLUCIÓN HIPERTÓNICA TAMPONADA, según reivindicaciones 1a y 3o, caracterizada porque la solución acuosa contiene un 8% de fosfato bisódico dodecahidratado y un 16% de fosfato monosódico monohidratado, según el porcentaje peso/volumen.4 .- SOLUTION OBTAINED BY THE PROCESS FOR OBTAINING A HYPERTONIC SOLUTION buffered, according to claims 1 and 3 or, characterized in that the aqueous solution contains 8% of disodium phosphate dodecahydrate and 16% of sodium dihydrogen phosphate monohydrate, according to the weight / volume percentage.
5a.- SOLUCIÓN OBTENIDA POR EL PROCEDIMIENTO PARA LA OBTENCIÓN DE UNA SOLUCIÓN HIPERTÓNICA TAMPONADA, según reivindicaciones 1a y 3o, caracterizada porque la solución acuosa contiene un 24% de fosfato bisódico dodecahidratado y un 48% de fosfato monosódico monohidratado, según el porcentaje peso/volumen.
5 .- SOLUTION OBTAINED BY THE PROCESS FOR OBTAINING A HYPERTONIC SOLUTION buffered, according to claims 1 and 3 or, characterized in that the aqueous solution contains 24% disodium phosphate dodecahydrate and 48% of sodium dihydrogen phosphate monohydrate, according to the weight / volume percentage.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200201324 | 2002-06-10 | ||
| ES200201324A ES2197817B2 (en) | 2002-06-10 | 2002-06-10 | PROCEDURE FOR OBTAINING A STAMPED HYPERTONIC SOLUTION AND OBTAINED SOLUTION. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003104146A1 true WO2003104146A1 (en) | 2003-12-18 |
Family
ID=29724721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/ES2003/000280 WO2003104146A1 (en) | 2002-06-10 | 2003-06-10 | Method of obtaining a buffered hypertonic solution and solution thus obtained |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2197817B2 (en) |
| WO (1) | WO2003104146A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES404975A1 (en) * | 1972-07-19 | 1975-07-01 | Roncales Sa | Procedure for the obtaining of a taped hypertonic solution. (Machine-translation by Google Translate, not legally binding) |
| ES8504625A2 (en) * | 1972-07-19 | 1985-05-16 | Fisons Iberica S A | Buffered hypertonic soln. |
| WO1985004552A1 (en) * | 1984-04-10 | 1985-10-24 | Baxter Travenol Laboratories, Inc. | Solutions of mitomycin |
-
2002
- 2002-06-10 ES ES200201324A patent/ES2197817B2/en not_active Expired - Fee Related
-
2003
- 2003-06-10 WO PCT/ES2003/000280 patent/WO2003104146A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES404975A1 (en) * | 1972-07-19 | 1975-07-01 | Roncales Sa | Procedure for the obtaining of a taped hypertonic solution. (Machine-translation by Google Translate, not legally binding) |
| ES8504625A2 (en) * | 1972-07-19 | 1985-05-16 | Fisons Iberica S A | Buffered hypertonic soln. |
| WO1985004552A1 (en) * | 1984-04-10 | 1985-10-24 | Baxter Travenol Laboratories, Inc. | Solutions of mitomycin |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2197817A1 (en) | 2004-01-01 |
| ES2197817B2 (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2841099T3 (en) | Bicarbonate-based solutions for dialysis therapies | |
| US5955067A (en) | Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea | |
| ES2289713T3 (en) | STABILIZED COMPOSITIONS THAT INCLUDE A THERAPEUTICALLY ACTIVE AGENT, CITRIC ACID OR A CONJUGATED BASE AND CHLORINE DIOXIDE. | |
| ES2285970T1 (en) | COLON CLEANING COMPOSITIONS. | |
| JP2015527385A5 (en) | ||
| JP2005510538A5 (en) | ||
| US20080274206A1 (en) | Stabilised Oxygen Releasing Composition | |
| JPH0641362B2 (en) | Stabilized active oxygen | |
| PE20050822A1 (en) | FLORPHENICOL DERIVATIVES WITH BETTER SOLUBILITY IN WATER | |
| IE60759B1 (en) | Pharmaceutical formulations | |
| JPH0670057B2 (en) | Guanine derivative crystalline monohydrate, method for producing the same and antiviral agent containing the same | |
| JP4395338B2 (en) | Pharmaceutical composition having antibiotic activity | |
| ES2946237T3 (en) | Two-component systems comprising acetylsalicylic acid and a carbonate salt | |
| ES2553107T3 (en) | Anti-inflammatory composition based on strontium compounds | |
| US2275979A (en) | Sodium perborate preparation | |
| UA79110C2 (en) | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders | |
| WO2003104146A1 (en) | Method of obtaining a buffered hypertonic solution and solution thus obtained | |
| ES2257559T3 (en) | PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF SODIUM 3-HYDROXY-3-METHYLBUTIRATE. | |
| ES2946260T3 (en) | Two-component systems comprising acetylsalicylic acid and a phosphate salt | |
| ES2245376T3 (en) | METHOD FOR THE PREPARATION OF A BIOCIDE CONCENTRATE. | |
| ES2277620T3 (en) | CALCIUM TRIFLUOROACETATE WITH CYTOTOXIC ACTIVITY. | |
| ES2215025T3 (en) | EFERVESCENT PHARMACEUTICAL FORMULATION, CONTAINING METAMIZOL. | |
| ES2242100T3 (en) | PREPARATION OF PURE STEREOISOMEROS OF TRICYCLE XANTOGENATE - (5.2.1.0 (2.6)) - DEC-9-ILO AND ITS USE AS MEDICATIONS. | |
| US2207074A (en) | Oxygen generating composition | |
| ES2337258T3 (en) | REACTIVE CHLORINE COMPOUNDS, THE DERIVATIVES, ANIONS AND SALTS OF THE SAME, METHODS FOR THEIR PRODUCTION AND USE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |